Photo from Polyak Lab/Twitter
Sep 11, 2023, 00:27
Our preclinical study evaluating the efficacy of BRD4 inhibitor+Paclitaxel+anti-PD-L1 combination for Triple negative breast cancer is out in Molecular Cancer Therapeutics today. – Polyak Lab
Polyak Lab recently shared on X/Twitter:
“Our preclinical study evaluating the efficacy of BRD4 inhibitor+Paclitaxel+anti-PD-L1 combination for TNBC is out in Molecular Cancer Therapeutics today. Congrats to all the coauthors! And of course a lot more to be explored in the future.”
For the article click here.
Source: Polyak Lab/Twitter